SG11201803369TA - Nicotinamide for use in the treatment and prevention of ocular neurodegenerative disorder (e.g. glaucoma) - Google Patents
Nicotinamide for use in the treatment and prevention of ocular neurodegenerative disorder (e.g. glaucoma)Info
- Publication number
- SG11201803369TA SG11201803369TA SG11201803369TA SG11201803369TA SG11201803369TA SG 11201803369T A SG11201803369T A SG 11201803369TA SG 11201803369T A SG11201803369T A SG 11201803369TA SG 11201803369T A SG11201803369T A SG 11201803369TA SG 11201803369T A SG11201803369T A SG 11201803369TA
- Authority
- SG
- Singapore
- Prior art keywords
- nicotinamide
- glaucoma
- prevention
- treatment
- neurodegenerative disorder
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/45—Transferases (2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/07—Nucleotidyltransferases (2.7.7)
- C12Y207/07001—Nicotinamide-nucleotide adenylyltransferase (2.7.7.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/07—Nucleotidyltransferases (2.7.7)
- C12Y207/07018—Nicotinate-nucleotide adenylyltransferase (2.7.7.18)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Ophthalmology & Optometry (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562245467P | 2015-10-23 | 2015-10-23 | |
| US201662366211P | 2016-07-25 | 2016-07-25 | |
| PCT/US2016/058388 WO2017070647A1 (fr) | 2015-10-23 | 2016-10-24 | Nicotinamide à utiliser dans le traitement et la prévention d'un trouble neurodégénératif oculaire (par exemple, un glaucome) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201803369TA true SG11201803369TA (en) | 2018-05-30 |
Family
ID=57281289
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201913165XA SG10201913165XA (en) | 2015-10-23 | 2016-10-24 | Nicotinamide for use in the treatment and prevention of ocular neurodegenerative disorder (e.g. glaucoma) |
| SG11201803369TA SG11201803369TA (en) | 2015-10-23 | 2016-10-24 | Nicotinamide for use in the treatment and prevention of ocular neurodegenerative disorder (e.g. glaucoma) |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201913165XA SG10201913165XA (en) | 2015-10-23 | 2016-10-24 | Nicotinamide for use in the treatment and prevention of ocular neurodegenerative disorder (e.g. glaucoma) |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US11389439B2 (fr) |
| EP (1) | EP3364973A1 (fr) |
| JP (3) | JP7089469B2 (fr) |
| CN (2) | CN115105500A (fr) |
| AU (2) | AU2016341314B2 (fr) |
| CA (1) | CA3003000A1 (fr) |
| IL (1) | IL258846A (fr) |
| SG (2) | SG10201913165XA (fr) |
| WO (1) | WO2017070647A1 (fr) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115105500A (zh) * | 2015-10-23 | 2022-09-27 | 杰克逊实验室 | 烟酰胺用于治疗和预防眼部神经退行性疾病如青光眼 |
| RS64644B9 (sr) | 2016-07-15 | 2024-02-29 | H2 Water Tech Ltd | Kompozicije za proizvodnju vode obogaćene vodonikom |
| WO2018195666A1 (fr) * | 2017-04-27 | 2018-11-01 | H2 Water Technologies Ltd | Compositions synergiques pour augmenter la fonction mitochondriale et la production d'énergie |
| US11564936B2 (en) | 2017-08-10 | 2023-01-31 | Washington University | Compositions and methods of treatment using nicotinamide mononucleotide |
| US20200384004A1 (en) * | 2017-12-01 | 2020-12-10 | Elysium Health, Inc. | Methods and compositions for treating glaucoma |
| CN108159434B (zh) * | 2018-01-29 | 2020-03-24 | 上海市第一人民医院 | 一种基因载体及其用于治疗青光眼的基因治疗药物 |
| CN109350622A (zh) * | 2018-10-17 | 2019-02-19 | 深圳市龙格生技术有限公司 | 烟酰胺核糖及其衍生物与吡咯喹啉醌及其钠盐的组合工艺 |
| CA3116729A1 (fr) * | 2018-10-19 | 2020-04-23 | Disarm Therapeutics, Inc. | Inhibiteurs de sarm1 en combinaison avec nad+ ou un precurseur de nad+ |
| US20220370484A1 (en) * | 2019-06-25 | 2022-11-24 | Senju Pharmaceutical Co., Ltd. | Novel use of nicotinamide mononucleotide (nmn) and nicotinamide riboside (nr) |
| AU2021236233A1 (en) * | 2020-03-11 | 2022-09-22 | Massachusetts Eye And Ear Infirmary | Gene therapy for NMNAT1-associated retinal degeneration |
| CN111518891B (zh) * | 2020-05-08 | 2023-01-10 | 青岛市中医医院(青岛市海慈医院、青岛市康复医学研究所) | Sp8基因作为诊治青光眼的生物标志物的用途 |
| CN112451494A (zh) * | 2020-11-11 | 2021-03-09 | 武汉林宝莱生物科技有限公司 | 一种吡咯喹啉醌配方及nmn制剂配方制备方法 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5464758A (en) | 1993-06-14 | 1995-11-07 | Gossen; Manfred | Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters |
| US6133027A (en) | 1996-08-07 | 2000-10-17 | City Of Hope | Inducible expression system |
| US6207455B1 (en) | 1997-05-01 | 2001-03-27 | Lung-Ji Chang | Lentiviral vectors |
| AU741747B2 (en) | 1997-05-13 | 2001-12-06 | University Of North Carolina At Chapel Hill, The | Lentivirus-based gene transfer vectors |
| US5994136A (en) | 1997-12-12 | 1999-11-30 | Cell Genesys, Inc. | Method and means for producing high titer, safe, recombinant lentivirus vectors |
| US6218181B1 (en) | 1998-03-18 | 2001-04-17 | The Salk Institute For Biological Studies | Retroviral packaging cell line |
| DE19909769A1 (de) | 1999-03-05 | 2000-09-07 | Bundesrepublik Deutschland Let | Von SIVagm abgeleitete lentivirale Vektoren, Verfahren zu ihrer Herstellung und ihre Verwendung zur Genübertragung in Säugerzellen |
| US20050037097A1 (en) | 2003-08-14 | 2005-02-17 | Neena Gandhi | Pyruvate enriched onion extract |
| WO2005113017A2 (fr) | 2004-04-22 | 2005-12-01 | Florida Atlantic University | Therapie genique a base de gfap pour le traitement des maladies de la retine |
| ES2557810T3 (es) * | 2004-06-04 | 2016-01-28 | Washington University | Métodos y composiciones para tratar neuropatías |
| CA2595942A1 (fr) | 2005-01-28 | 2006-08-03 | Children's Hospital Of Eastern Ontario | Traitement de maladies degeneratives faisant appel a l'inhibiteur de l'apoptose lie au chromosome x |
| US20060211744A1 (en) | 2005-03-21 | 2006-09-21 | Children's Medical Center | 3-Pyridinecarboxamide reduces nerve degeneration |
| KR20090102810A (ko) | 2006-12-26 | 2009-09-30 | 큐엘티 플러그 딜리버리, 인코포레이티드 | 시력 결함을 억제하기 위한 약물 전달 임플란트 |
| ES2893199T3 (es) | 2010-03-29 | 2022-02-08 | Alnylam Pharmaceuticals Inc | Terapia de ARNbc para amiloidosis ocular relacionada con transtiretina (TTR) |
| CN115105500A (zh) * | 2015-10-23 | 2022-09-27 | 杰克逊实验室 | 烟酰胺用于治疗和预防眼部神经退行性疾病如青光眼 |
-
2016
- 2016-10-24 CN CN202210885772.2A patent/CN115105500A/zh active Pending
- 2016-10-24 SG SG10201913165XA patent/SG10201913165XA/en unknown
- 2016-10-24 CN CN201680075950.8A patent/CN108883105B/zh active Active
- 2016-10-24 SG SG11201803369TA patent/SG11201803369TA/en unknown
- 2016-10-24 AU AU2016341314A patent/AU2016341314B2/en active Active
- 2016-10-24 WO PCT/US2016/058388 patent/WO2017070647A1/fr active Application Filing
- 2016-10-24 CA CA3003000A patent/CA3003000A1/fr active Pending
- 2016-10-24 EP EP16794470.1A patent/EP3364973A1/fr active Pending
- 2016-10-24 JP JP2018521064A patent/JP7089469B2/ja active Active
-
2018
- 2018-04-22 IL IL258846A patent/IL258846A/en unknown
- 2018-04-23 US US15/959,379 patent/US11389439B2/en active Active
-
2022
- 2022-06-10 JP JP2022094110A patent/JP7312886B2/ja active Active
- 2022-07-12 US US17/862,668 patent/US20220354838A1/en active Pending
- 2022-07-28 AU AU2022209298A patent/AU2022209298A1/en active Pending
-
2023
- 2023-07-10 JP JP2023112950A patent/JP2023123873A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP7089469B2 (ja) | 2022-06-22 |
| US20180344719A1 (en) | 2018-12-06 |
| CN108883105B (zh) | 2022-07-15 |
| AU2016341314A1 (en) | 2018-05-10 |
| US20220354838A1 (en) | 2022-11-10 |
| AU2022209298A1 (en) | 2022-08-25 |
| CA3003000A1 (fr) | 2017-04-27 |
| KR20180066229A (ko) | 2018-06-18 |
| US11389439B2 (en) | 2022-07-19 |
| WO2017070647A8 (fr) | 2017-06-08 |
| AU2016341314B2 (en) | 2022-05-19 |
| IL258846A (en) | 2018-06-28 |
| CN108883105A (zh) | 2018-11-23 |
| JP7312886B2 (ja) | 2023-07-21 |
| WO2017070647A1 (fr) | 2017-04-27 |
| CN115105500A (zh) | 2022-09-27 |
| EP3364973A1 (fr) | 2018-08-29 |
| JP2018535956A (ja) | 2018-12-06 |
| JP2023123873A (ja) | 2023-09-05 |
| SG10201913165XA (en) | 2020-02-27 |
| JP2022120098A (ja) | 2022-08-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL258846A (en) | Nicotinamide for use in the treatment and prevention of optic neurodegenerative disorder | |
| HK1219784A1 (zh) | 高加治療區鏡片設計以及用於預防和/或減慢近視發展的方法 | |
| GB201411496D0 (en) | Use of 7-Oh-Cannabidiol (7-Oh-CBD) and/or 7-Oh-Cannabidvarin (7-Oh-CBDV) in the treatment of epilepsy | |
| EP3212137A4 (fr) | Systèmes et procédés pour le traitement d'affections oculaires | |
| GB201405232D0 (en) | Apparatus and methods for the treatment of ocular disorders | |
| ZA201705634B (en) | Quinoline derivatives for use in the treatment or prevention of viral infection | |
| ZA202002066B (en) | Compositions and methods for the treatment of eye disorders | |
| EP3481453A4 (fr) | Dispositifs et procédés de traitement du glaucome | |
| IL263477A (en) | Compositions and methods for the treatment or prevention of oxalate-related disorders | |
| IL247435A0 (en) | Pyridazine derivatives for use in the prevention of or treatment of ataxic disorder | |
| PL3122367T3 (pl) | Kompozycje na bazie szafranu do zapobiegania i/lub leczenia chorób zwyrodnieniowych oka | |
| EP3199163A4 (fr) | Composition de doxycycline dans des liposomes pour la prévention, l'amélioration et/ou le traitement de pathologies oculaires | |
| EP3208262A4 (fr) | Composés dérivés d'acrylate de 3-alkylamine-1h-indolyle et leur utilisation dans le traitement de maladies neurodégénératives | |
| EP3131635A4 (fr) | Compositions et méthodes de traitement ou de prévention de la tuberculose | |
| EP3302684A4 (fr) | Méthodes et dispositifs de traitement de la cornée | |
| ZA201806894B (en) | (+)-azasetron for use in the treatment of ear disorders | |
| IL259383A (en) | A compound for use in the prevention and treatment of neurodegenerative diseases | |
| GB201617715D0 (en) | Methods for the treatment and prevention of ebola | |
| EP3284475A4 (fr) | Agent pour la prévention ou le traitement de troubles de la cornée | |
| PT3442537T (pt) | (+)-azasetrom para utilização no tratamento de doenças do ouvido | |
| GB201522828D0 (en) | Prevention and treatment of glaucoma | |
| GB201617591D0 (en) | Methods for the treatment and prevention of ebola | |
| GB201617590D0 (en) | Methods for the treatment and prevention of ebola | |
| GB201518489D0 (en) | Methods for the treatment and prevention of ebola | |
| AU2014901398A0 (en) | Compositions and methods for the treatment or prevention of neurodegenerative disorders |